Therefore, additional studies of the PPARγ Pro12Ala polymorphism are necessary to fully elucidate the role of PPAR genetics in obesity independent of CVD, particularly with regard to available pharmacological PPAR-targeted agents. The gene discussed is PPARA; the disease is obesity due to melanocortin 4 receptor deficiency.